Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes.

[1]  P. Marcellin Viral hepatitis: towards the eradication of HCV and a cure for HBV , 2016, Liver international (Print).

[2]  T. Asselah,et al.  Viral hepatitis: towards the eradication of HCV and a cure for HBV , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[3]  A. Alibrandi,et al.  Hepatitis B virus (HBV) induces the expression of interleukin-8 that in turn reduces HBV sensitivity to interferon-alpha. , 2013, Virology.

[4]  Yongjung Park,et al.  Serum cytokine levels in chronic hepatitis B patients receiving peginterferon alpha-2a therapy. , 2012, Hepatobiliary & pancreatic diseases international : HBPD INT.

[5]  J. Long,et al.  Exome sequencing generates high quality data in non-target regions , 2012, BMC Genomics.

[6]  Alina Macovei,et al.  Activation of ERAD Pathway by Human Hepatitis B Virus Modulates Viral and Subviral Particle Production , 2012, PloS one.

[7]  M. Imamura,et al.  Effects of hepatitis B virus infection on the interferon response in immunodeficient human hepatocyte chimeric mice. , 2011, The Journal of infectious diseases.

[8]  K. Simon,et al.  A Randomized Trial of Peginterferon α-2a With or Without Ribavirin for HBeAg-Negative Chronic Hepatitis B , 2010, The American Journal of Gastroenterology.

[9]  Yoshiyuki Suzuki,et al.  Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment , 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

[10]  H. Nomura,et al.  Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan , 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

[11]  F. Zoulim,et al.  Hepatitis B virus resistance to nucleos(t)ide analogues. , 2009, Gastroenterology.

[12]  B. Rollins Where the Confusion Began: Cloning the First Chemokine Receptors , 2009, The Journal of Immunology.

[13]  M. Imamura,et al.  Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice. , 2008, The Journal of general virology.

[14]  J. Van Damme,et al.  The role of CXC chemokines and their receptors in cancer. , 2008, Cancer letters.

[15]  Yoshiyuki Suzuki,et al.  Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. , 2008, Journal of hepatology.

[16]  M. Imamura,et al.  Successful treatment of an entecavir‐resistant hepatitis B virus variant , 2007, Journal of medical virology.

[17]  Angeline Bartholomeusz,et al.  Antiviral drug‐resistant HBV: Standardization of nomenclature and assays and recommendations for management , 2007, Hepatology.

[18]  M. Imamura,et al.  Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon , 2007, FEBS letters.

[19]  T. Liang,et al.  Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. , 2007, Gastroenterology.

[20]  P. Borrow,et al.  Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell–mediated liver damage , 2007, The Journal of experimental medicine.

[21]  C. Mazzucco,et al.  Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present , 2006, Antimicrobial Agents and Chemotherapy.

[22]  S. Zeuzem,et al.  Patterns of viral decline during PEG‐interferon alpha‐2b therapy in HBeAg‐positive chronic hepatitis B: Relation to treatment response , 2006, Hepatology.

[23]  I. Su,et al.  Hepatitis B virus pre‐S mutants, endoplasmic reticulum stress and hepatocarcinogenesis , 2006, Cancer science.

[24]  H. Lee,et al.  Increased risk of adefovir resistance in patients with lamivudine‐resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy , 2006, Hepatology.

[25]  M. Katze,et al.  Application of functional genomics to the chimeric mouse model of HCV infection: optimization of microarray protocols and genomics analysis , 2006, Virology Journal.

[26]  Z. Szallasi,et al.  Reliability and reproducibility issues in DNA microarray measurements. , 2006, Trends in genetics : TIG.

[27]  M. Imamura,et al.  Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus , 2005, Hepatology.

[28]  T. Okanoue,et al.  Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas , 2005, Gut.

[29]  John Quackenbush,et al.  Multiple-laboratory comparison of microarray platforms , 2005, Nature Methods.

[30]  P. Marcellin,et al.  Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. , 2004, The New England journal of medicine.

[31]  T. Asahara,et al.  Near completely humanized liver in mice shows human-type metabolic responses to drugs. , 2004, The American journal of pathology.

[32]  P. Angus,et al.  Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine , 2004, Antimicrobial Agents and Chemotherapy.

[33]  R. Purcell,et al.  Genomic analysis of the host response to hepatitis B virus infection. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Yoshiyuki Suzuki,et al.  Efficacy of Lamivudine Therapy and Factors Associated with Emergence of Resistance in Chronic Hepatitis B Virus Infection in Japan , 2003, Intervirology.

[35]  H. Conjeevaram,et al.  Management of chronic hepatitis B. , 2003, Journal of hepatology.

[36]  D. Tyrrell,et al.  Hepatitis C virus replication in mice with chimeric human livers , 2001, Nature Medicine.

[37]  C. Bréchot,et al.  Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). , 2000, Seminars in cancer biology.

[38]  K. Chayama,et al.  Emergence and takeover of YMDD motif mutant hepatitis B virus during long‐term lamivudine therapy and re‐takeover by wild type after cessation of therapy , 1998, Hepatology.

[39]  M. Buti,et al.  Transient emergence of hepatitis B variants in a patient with chronic hepatitis B resistant to lamivudine. , 1998, Journal of hepatology.

[40]  F. Su,et al.  Hepatitis B virus HBx protein activates transcription factor NF-kappaB by acting on multiple cytoplasmic inhibitors of rel-related proteins , 1996, Journal of virology.

[41]  D. Schadendorf,et al.  IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. , 1993, Journal of immunology.

[42]  K. Matsushima,et al.  Interleukin-8 and MCAF: novel leukocyte recruitment and activating cytokines. , 1992, Chemical immunology.

[43]  T. Tokino,et al.  The mode of hepatitis B virus DNA integration in chromosomes of human hepatocellular carcinoma. , 1987, Genes & development.

[44]  K. Koike,et al.  Multiple integration site of hepatitis B virus DNA in hepatocellular carcinoma and chronic active hepatitis tissues from children , 1987, Journal of virology.

[45]  H. Hsu,et al.  Diverse virological, histopathological and prognostic implications of seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection. , 1986, Journal of hepatology.

[46]  F. Schaffner,et al.  Electron microscopy and immunoelectronmicroscopy of cytoplasmic hepatitis B antigen in hepatocytes. , 1974, The American journal of pathology.